Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
Want to see BRNS full AI Analyst Report?
BRNS Stock Chart & Stats
$0.76
>-$0.01(-0.43%)
At close: 4:00 PM EST
$0.76
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$0.51 - $2.92
Previous CloseN/A
Volume10.26K
Average Volume (3M)124.73K
Market Cap
$26.58M
Enterprise Value-$28.27M
Total Cash (Recent Filing)$67.19M
Total Debt (Recent Filing)$11.01M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Aug 06, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap-1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.04
Enterprise Value/Ebitda0.57
Forecast
1Y Price Target
$7.00Price Target Upside821.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage On Balance SheetLow absolute debt gives Barinthus structural financial flexibility versus highly leveraged peers. With modest debt levels, the company can prioritize financing operating needs, support clinical programs, or absorb short-term shocks without immediate pressure from interest or covenant constraints, aiding multi-quarter stability.
Merger Provides Multi-year Cash RunwayThe announced all-stock merger with Clywedog is a structural financing and strategic event that extends runway through 2027, enabling planned clinical milestones. This reduces near-term fundraising pressure, supports continued development of VTP-1000, and gives management time to pursue value-accretive readouts.
Appointment Of Experienced CFOBringing a seasoned CFO with prior biotech finance leadership strengthens governance and capital allocation. Durable benefits include improved financial controls, more effective investor communications, and enhanced execution of complex transactions or financing strategies across the next several quarters.
Bears Say
Persistent Negative Operating Cash FlowConsistent and deep negative operating and free cash flow indicate the business structurally consumes cash to fund R&D and operations. Over multiple quarters this forces reliance on external capital, increases dilution risk, and constrains discretionary investments absent sustained profitability or deal financing.
Revenue Instability And Widening LossesVolatile revenue with a fall to zero and a shift from profit to material losses reflect absence of a stable commercial base. This undermines long-term cash predictability, reduces milestone/partnership leverage, and makes multi-quarter planning and hiring/product commercialization decisions more uncertain.
Complex Cross-border Merger Execution RiskThe cross-border, multi-entity merger structure and recent amendments show execution complexity and timing risk. Continued renegotiation of ratios and cash covenants can alter shareholder dilution, delay realization of synergies, and leave the company exposed if closing conditions or regulatory timing weaken capital assumptions.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.51 and its highest was $2.92 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $26.58M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 93 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Apr 30, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.14.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.28.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,848,892 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 8.514%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
BRNS Stock 12 Month Forecast
Average Price Target
$7.00
▲(821.05% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
0.19%
Insiders
0.03% Mutual Funds
18.28% Other Institutional Investors
81.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---